Luminex Corporation Company Profile (NASDAQ:LMNX)

About Luminex Corporation (NASDAQ:LMNX)

Luminex Corporation logoLuminex Corporation develops, manufactures and sells biological testing technologies with applications throughout the diagnostics, pharmaceutical and life sciences industries. The Company's products are focused on the molecular diagnostic testing market, which includes human genetics, personalized medicine and infectious disease segments. The Company has a range of instruments using its xMAP technology, which includes its LUMINEX 100/200 systems offer 100-plex testing; the Company's FLEXMAP 3D system is its high-throughput, 500-plex testing system, and its MAGPIX system provides 50-plex testing using imaging rather than flow cytometry. By using its xMAP technology, the end users are able to generate multiple simultaneous results per sample. The Company primarily serves the diagnostics, pharmaceutical and life sciences industries by marketing products, including its testing equipment and assays, to a range of testing laboratories.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Advanced Medical Equipment & Technology - NEC
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NASDAQ:LMNX
  • CUSIP: 55027E10
  • Web:
  • Market Cap: $909.71 million
  • Outstanding Shares: 43,926,000
Average Prices:
  • 50 Day Moving Avg: $20.84
  • 200 Day Moving Avg: $19.66
  • 52 Week Range: $17.64 - $23.75
  • Trailing P/E Ratio: 64.32
  • Foreward P/E Ratio: 32.87
  • P/E Growth: 0.71
Sales & Book Value:
  • Annual Revenue: $285.44 million
  • Price / Sales: 3.19
  • Book Value: $9.51 per share
  • Price / Book: 2.18
  • Annual Dividend: $0.24
  • Dividend Yield: 1.2%
  • EBIDTA: $50.46 million
  • Net Margins: 5.00%
  • Return on Equity: 5.48%
  • Return on Assets: 4.98%
  • Current Ratio: 5.79%
  • Quick Ratio: 4.34%
  • Average Volume: 232,465 shs.
  • Beta: 0.29
  • Short Ratio: 9.92
Frequently Asked Questions for Luminex Corporation (NASDAQ:LMNX)

What is Luminex Corporation's stock symbol?

Luminex Corporation trades on the NASDAQ under the ticker symbol "LMNX."

How often does Luminex Corporation pay dividends? What is the dividend yield for Luminex Corporation?

Luminex Corporation declared a quarterly dividend on Thursday, May 25th. Investors of record on Friday, June 23rd will be paid a dividend of $0.06 per share on Friday, July 14th. This represents a $0.24 dividend on an annualized basis and a dividend yield of 1.16%. The ex-dividend date of this dividend is Wednesday, June 21st. View Luminex Corporation's Dividend History.

How were Luminex Corporation's earnings last quarter?

Luminex Corporation (NASDAQ:LMNX) issued its quarterly earnings data on Monday, May, 1st. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.16 by $0.12. The firm had revenue of $77.80 million for the quarter, compared to analysts' expectations of $74.25 million. Luminex Corporation had a return on equity of 5.48% and a net margin of 5.00%. The company's revenue was up 23.5% on a year-over-year basis. During the same period last year, the company earned $0.29 EPS. View Luminex Corporation's Earnings History.

Where is Luminex Corporation's stock going? Where will Luminex Corporation's stock price be in 2017?

6 equities research analysts have issued 1-year price targets for Luminex Corporation's stock. Their predictions range from $18.00 to $27.00. On average, they expect Luminex Corporation's stock price to reach $21.40 in the next twelve months. View Analyst Ratings for Luminex Corporation.

What are analysts saying about Luminex Corporation stock?

Here are some recent quotes from research analysts about Luminex Corporation stock:

  • 1. According to Zacks Investment Research, "Luminex’s Assay business will be its key growth driver over the long term. The company also witnessed favorable tidings at the regulatory-front of late. In this regard, the reimbursement approval of VERIGENE assay in Japan and FDA clearance of Bordetella Assay are noteworthy. We are also optimistic about the company’s products – ARIES and NxTAG RPP – which represent a major revenue opportunity.  Luminex reported stable first-quarter 2017 results, beating the Zacks Consensus Estimates on both lines. Also the weakness in stock price over the past on year has made valuation very compelling. Finally Luminex has a broad product portfolio that comprises of its advanced xMAP, xTAG and MultiCode technology. The company’s large installed instrument base and collaborative agreements with several companies would also help expand the use of its products." (7/17/2017)
  • 2. Piper Jaffray Companies analysts commented, "Luminex announced 4Q16 revenue of $72.3M, in line with preliminary results. Adj. EPS of $0.06 missed the Street's $0.13 estimate. Results in the quarter reflect strong consumables growth, somewhat offset by lighter instrument sales. Management reaffirmed FY17 revenue guidance of $295M-$305M and provided 1Q17 revenue guidance in line with the Street ($73M-$75M; Street: $74.2M). Revenue guidance appears achievable, but we believe shares are fairly valued. We remain Neutral with a $19 price target (was $20) based on ~2.1x FY18 EV/Rev (unchanged) on our revised estimates." (2/7/2017)

Who are some of Luminex Corporation's key competitors?

Who are Luminex Corporation's key executives?

Luminex Corporation's management team includes the folowing people:

  • G. Walter Loewenbaum II, Independent Chairman of the Board
  • Nachum Shamir, President, Chief Executive Officer, Director
  • Harriss T. Currie, Chief Financial Officer, Senior Vice President - Finance, Treasurer
  • Richard W. Rew II, Senior Vice President, General Counsel, Secretary
  • Nancy M. Fairchild, Senior Vice President - Human resources
  • Randall Myers, Senior Vice President - Global Manufacturing and Quality
  • Robert J. Cresci, Independent Director
  • Stephen L Eck, Independent Director
  • Thomas Willard Erickson, Independent Director
  • Jimmy Dale Kever, Independent Director

Who owns Luminex Corporation stock?

Luminex Corporation's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Thomson Horstmann & Bryant Inc. (0.94%), CWM LLC (0.41%), Fisher Asset Management LLC (0.15%), Eqis Capital Management Inc. (0.10%), Bank of Montreal Can (0.09%) and Aperio Group LLC (0.08%). Company insiders that own Luminex Corporation stock include G Walter Loewenbaum II, Harriss T Currie, Kevin M Mcnamara, Nachum Shamir and Russell W Bradley. View Institutional Ownership Trends for Luminex Corporation.

Who sold Luminex Corporation stock? Who is selling Luminex Corporation stock?

Luminex Corporation's stock was sold by a variety of institutional investors in the last quarter, including CWM LLC, Bank of Montreal Can, Capstone Asset Management Co. and Creative Planning. Company insiders that have sold Luminex Corporation stock in the last year include G Walter Loewenbaum II and Kevin M Mcnamara. View Insider Buying and Selling for Luminex Corporation.

Who bought Luminex Corporation stock? Who is buying Luminex Corporation stock?

Luminex Corporation's stock was acquired by a variety of institutional investors in the last quarter, including Aperio Group LLC, Fisher Asset Management LLC, Thomson Horstmann & Bryant Inc., State of Alaska Department of Revenue, Eqis Capital Management Inc., Louisiana State Employees Retirement System and McQueen Ball & Associates Inc.. Company insiders that have bought Luminex Corporation stock in the last two years include Harriss T Currie and Nachum Shamir. View Insider Buying and Selling for Luminex Corporation.

How do I buy Luminex Corporation stock?

Shares of Luminex Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Luminex Corporation's stock price today?

One share of Luminex Corporation stock can currently be purchased for approximately $20.71.

MarketBeat Community Rating for Luminex Corporation (NASDAQ LMNX)
Community Ranking:  1.2 out of 5 ()
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  203 (Vote Underperform)
Total Votes:  267
MarketBeat's community ratings are surveys of what our community members think about Luminex Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Luminex Corporation (NASDAQ:LMNX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $21.40 (3.33% upside)

Analysts' Ratings History for Luminex Corporation (NASDAQ:LMNX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
6/9/2017Jefferies Group LLCReiterated RatingHold$21.00LowView Rating Details
2/7/2017Piper Jaffray CompaniesLower Price TargetNeutral$20.00 -> $19.00N/AView Rating Details
2/7/2017William BlairReiterated RatingMarket PerformN/AView Rating Details
1/18/2017Deutsche Bank AGReiterated RatingSell$18.00N/AView Rating Details
10/12/2016Avondale PartnersInitiated CoverageOutperform$27.00N/AView Rating Details
8/18/2016J P Morgan Chase & CoUpgradeUnderweight -> Neutral$18.00 -> $22.00N/AView Rating Details
5/3/2016Leerink SwannReiterated RatingHold$22.00N/AView Rating Details
8/4/2015WedbushUpgradeNeutral -> Outperform$19.00 -> $22.00N/AView Rating Details
(Data available from 7/24/2015 forward)


Earnings History for Luminex Corporation (NASDAQ:LMNX)
Earnings by Quarter for Luminex Corporation (NASDAQ:LMNX)
Earnings History by Quarter for Luminex Corporation (NASDAQ LMNX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017Q1 2017$0.16$0.28$74.25 million$77.80 millionViewListenView Earnings Details
2/6/2017Q4 2016$0.09$0.11$70.92 million$72.30 millionViewListenView Earnings Details
10/31/2016Q316$0.12$0.21$68.90 million$71.20 millionViewListenView Earnings Details
7/28/2016Q216$0.18$0.33$61.20 million$64.20 millionViewListenView Earnings Details
5/2/2016Q116$0.14$0.29$60.98 million$63.00 millionViewListenView Earnings Details
11/2/2015Q315$0.11$0.17$57.24 million$60.60 millionViewListenView Earnings Details
8/3/2015Q215$0.12$0.27$57.01 million$58.90 millionViewListenView Earnings Details
5/4/2015Q115$0.12$0.23$56.50 million$57.70 millionViewListenView Earnings Details
2/2/2015Q414$0.12$0.19$58.31 million$58.10 millionViewListenView Earnings Details
10/27/2014Q314$0.10$0.27$56.60 million$56.68 millionViewListenView Earnings Details
7/28/2014Q214$0.10$0.20$55.90 million$55.50 millionViewListenView Earnings Details
4/28/2014Q114$0.12$0.24$55.31 million$56.60 millionViewListenView Earnings Details
2/3/2014Q413$0.07$0.21$56.63 million$55.20 millionViewListenView Earnings Details
11/4/2013Q313$0.11$0.02$54.67 million$50.80 millionViewListenView Earnings Details
7/29/2013Q2 2013$0.10$0.17$54.16 million$54.30 millionViewListenView Earnings Details
4/29/2013Q1 2013$0.08$0.19$51.94 million$53.20 millionViewListenView Earnings Details
2/4/2013Q4 2012$0.08$0.12$54.09 million$55.53 millionViewListenView Earnings Details
10/29/2012Q312$0.06$0.04$51.26 million$50.00 millionViewN/AView Earnings Details
7/30/2012$0.08$0.07ViewN/AView Earnings Details
4/30/2012$0.09$0.08ViewN/AView Earnings Details
2/6/2012$0.07$0.11ViewN/AView Earnings Details
11/1/2011$0.05$0.05ViewN/AView Earnings Details
8/8/2011$0.06$0.11ViewN/AView Earnings Details
5/9/2011$0.06$0.11ViewN/AView Earnings Details
2/7/2011$0.05$0.07ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Luminex Corporation (NASDAQ:LMNX)
2017 EPS Consensus Estimate: $0.24
2018 EPS Consensus Estimate: $0.45
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.09$0.09$0.09
Q2 20171$0.06$0.06$0.06
Q3 20171$0.06$0.06$0.06
Q4 20171$0.03$0.03$0.03
Q1 20181$0.12$0.12$0.12
Q2 20181$0.11$0.11$0.11
Q3 20181$0.11$0.11$0.11
Q4 20181$0.11$0.11$0.11
(Data provided by Zacks Investment Research)


Current Dividend Information for Luminex Corporation (NASDAQ:LMNX)
Most Recent Dividend:7/14/2017
Annual Dividend:$0.24
Dividend Yield:1.16%
Payout Ratio:75.00% (Trailing 12 Months of Earnings)
43.64% (Based on This Year's Estimates)
38.10% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Luminex Corporation (NASDAQ:LMNX)

Dividend History by Quarter for Luminex Corporation (NASDAQ LMNX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Luminex Corporation (NASDAQ:LMNX)
Insider Ownership Percentage: 6.90%
Institutional Ownership Percentage: 77.20%
Insider Trades by Quarter for Luminex Corporation (NASDAQ:LMNX)
Institutional Ownership by Quarter for Luminex Corporation (NASDAQ:LMNX)
Insider Trades by Quarter for Luminex Corporation (NASDAQ:LMNX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/30/2017G Walter Loewenbaum IIDirectorSell25,000$20.07$501,750.00View SEC Filing  
5/23/2017G Walter Loewenbaum IIDirectorSell25,000$20.23$505,750.00View SEC Filing  
5/18/2017G Walter Loewenbaum IIDirectorSell25,000$20.80$520,000.00View SEC Filing  
1/26/2017G Walter Loewenbaum IIDirectorSell20,000$19.75$395,000.00View SEC Filing  
1/19/2017G Walter Loewenbaum IIDirectorSell20,000$19.82$396,400.00View SEC Filing  
1/12/2017G Walter Loewenbaum IIDirectorSell20,000$20.43$408,600.00View SEC Filing  
1/5/2017G Walter Loewenbaum IIDirectorSell20,000$20.32$406,400.00View SEC Filing  
12/29/2016G Walter Loewenbaum IIDirectorSell20,000$20.27$405,400.00View SEC Filing  
11/28/2016G Walter Loewenbaum IIDirectorSell50,000$20.57$1,028,500.00View SEC Filing  
11/15/2016Kevin M McnamaraDirectorSell12,000$21.03$252,360.00View SEC Filing  
11/3/2016Harriss T. CurrieSVPBuy4,100$18.20$74,620.00View SEC Filing  
11/3/2016Nachum ShamirCEOBuy6,000$18.22$109,320.00View SEC Filing  
1/4/2016G Walter Loewenbaum IIDirectorSell41,056$20.53$842,879.68View SEC Filing  
12/31/2015G Walter Loewenbaum IIDirectorSell18,944$21.65$410,137.60View SEC Filing  
12/16/2015Russell W. BradleyCMOSell6,514$22.75$148,193.50View SEC Filing  
5/28/2015Nachum ShamirCEOBuy6,000$16.73$100,380.00View SEC Filing  
5/27/2015G Walter Loewenbaum IIDirectorBuy38,966$16.71$651,121.86View SEC Filing  
2/5/2015Fred C Goad JrDirectorSell25,000$15.46$386,500.00View SEC Filing  
10/8/2014Russell W BradleySVPSell5,000$20.50$102,500.00View SEC Filing  
5/15/2014Patrick BalthropCEOSell70,000$17.69$1,238,300.00View SEC Filing  
5/12/2014Kevin McnamaraDirectorSell5,000$17.95$89,750.00View SEC Filing  
5/9/2014Jim KeverDirectorSell5,000$17.52$87,600.00View SEC Filing  
5/7/2014Patrick BalthropCEOSell32,575$17.63$574,297.25View SEC Filing  
5/6/2014Patrick BalthropCEOSell60,000$18.28$1,096,800.00View SEC Filing  
5/2/2014Fred Goad, Jr.DirectorSell50,000$18.86$943,000.00View SEC Filing  
5/2/2014Patrick BalthropCEOSell55,000$19.05$1,047,750.00View SEC Filing  
5/1/2014David ReiterSVPSell15,000$19.09$286,350.00View SEC Filing  
5/1/2014Harriss CurrieCFOSell11,000$19.08$209,880.00View SEC Filing  
9/23/2013Harriss CurrieCFOSell30,000$19.88$596,400.00View SEC Filing  
9/17/2013Harriss CurrieCFOSell30,000$19.87$596,100.00View SEC Filing  
9/13/2013Michael PintekSVPSell3,000$20.00$60,000.00View SEC Filing  
8/30/2013G Walter Loewenbaum IIDirectorBuy6,034$20.62$124,421.08View SEC Filing  
8/28/2013G Walter Loewenbaum IIDirectorBuy20,000$20.76$415,200.00View SEC Filing  
8/16/2013Timothy DehneVPSell32,297$20.66$667,256.02View SEC Filing  
8/15/2013G Walter Loewenbaum IIDirectorBuy10,000$20.82$208,200.00View SEC Filing  
8/14/2013Timothy DehneVPSell1,793$21.21$38,029.53View SEC Filing  
8/9/2013G Walter Loewenbaum IIDirectorBuy4,600$21.17$97,382.00View SEC Filing  
8/2/2013G Walter Loewenbaum IIDirectorBuy27,000$20.01$540,270.00View SEC Filing  
8/2/2013Patrick J BalthropCEOSell68,048$20.01$1,361,640.48View SEC Filing  
8/1/2013David S ReiterSVPSell15,000$20.00$300,000.00View SEC Filing  
8/1/2013Thomas W EricksonDirectorSell20,000$20.00$400,000.00View SEC Filing  
5/24/2013Fred C Goad JrDirectorBuy11,250$18.25$205,312.50View SEC Filing  
5/17/2013G Walter Loewenbaum IIDirectorBuy13,000$18.37$238,810.00View SEC Filing  
5/16/2013Fred C Goad JrDirectorBuy8,000$18.18$145,440.00View SEC Filing  
5/15/2013G Walter Loewenbaum IIDirectorBuy39,500$18.32$723,640.00View SEC Filing  
5/10/2013David S ReiterSVPSell10,000$18.26$182,600.00View SEC Filing  
5/10/2013G Walter Loewenbaum IIDirectorBuy19,000$18.13$344,470.00View SEC Filing  
5/9/2013G Walter Loewenbaum IIDirectorBuy28,300$17.21$487,043.00View SEC Filing  
5/7/2013G Walter Loewenbaum IIDirectorBuy64,935$17.17$1,114,933.95View SEC Filing  
5/3/2013G Walter Loewenbaum IIDirectorBuy24,765$17.02$421,500.30View SEC Filing  
9/4/2012David S ReiterVPSell10,000$20.00$200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Luminex Corporation (NASDAQ:LMNX)
Latest Headlines for Luminex Corporation (NASDAQ:LMNX)
DateHeadline logoHead to Head Review: LeMaitre Vascular (LMAT) versus Luminex Corporation (LMNX) - July 20 at 10:16 PM logoLuminex Corporation Second Quarter Earnings Release Scheduled for August 7, 2017 - July 17 at 12:57 PM logoZacks Investment Research Upgrades Luminex Corporation (LMNX) to "Buy" - July 17 at 12:53 PM logoETFs with exposure to Luminex Corp. : July 14, 2017 - July 15 at 6:01 AM logoLuminex Corp. breached its 50 day moving average in a Bullish Manner : LMNX-US : July 10, 2017 - July 11 at 12:22 AM logoLuminex Corporation (NASDAQ:LMNX) Given Average Recommendation of "Hold" by Brokerages - July 10 at 3:08 PM logoLuminex Corporation (NASDAQ:LMNX) Downgraded by ValuEngine - July 8 at 10:10 PM logo$75.18 Million in Sales Expected for Luminex Corporation (NASDAQ:LMNX) This Quarter - July 6 at 10:31 AM logoLuminex Corporation (NASDAQ:LMNX) Expected to Announce Earnings of $0.11 Per Share - July 4 at 6:24 PM logoLuminex Corporation (LMNX) Rating Lowered to Hold at Zacks Investment Research - July 4 at 10:48 AM logoLuminex Corp. (LMNX) Announces Receipt of CE-IVD Mark for ARIES Norovirus Assay - June 30 at 11:46 PM logoLuminex Gets CE Mark for ARIES Norovirus Assay, Shares Rally - June 30 at 1:07 AM logoLuminex Corporation Receives CE-IVD Mark for ARIES® Norovirus Assay - June 28 at 7:57 PM logoLuminex receives CE-IVD mark for ARIES Norovirus Assay - June 28 at 9:04 AM logoConforMIS (CFMS) Gets FDA Approval for iTotal Hip System - June 26 at 9:24 AM logoEvolent Health (EVH) Prices 4.5M Follow-On Share Offering - June 23 at 7:46 AM logoETFs with exposure to Luminex Corp. : June 19, 2017 - June 19 at 5:21 PM logoDENTSPLY (XRAY) Renews Partnership with Pacific Dental - June 19 at 11:49 AM logoLuminex Corp. :LMNX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 - June 16 at 7:14 PM logoCONMED (CNMD) Hits a 52-Week High: What's Driving the Stock? - June 14 at 10:24 AM logoLuminex Corporation (LMNX) Given Average Rating of "Hold" by Analysts - June 13 at 12:50 PM logoZacks: Brokerages Anticipate Luminex Co. (LMNX) Will Announce Quarterly Sales of $75.18 Million - June 10 at 8:24 AM logoLuminex Co. (LMNX) Rating Reiterated by Jefferies Group LLC - June 9 at 5:08 PM logoLuminex Co. (LMNX) Expected to Announce Earnings of $0.11 Per Share - June 8 at 4:30 PM logoFeatured Company News - Luminex's VERIGENE Gram-Positive and Gram-Negative Blood Culture Panels Receive Reimbursement Approval in Japan - June 7 at 9:29 AM logoLuminex Corporation's VERIGENE Gram-Positive and Gram-Negative Blood Culture Panels Receive Reimbursement Approval in Japan - June 5 at 9:45 AM logoPatterson Companies Grapples With Multiple Issues: Dump Now? - June 2 at 7:43 PM logoG Walter Loewenbaum II Sells 25,000 Shares of Luminex Co. (LMNX) Stock - June 1 at 4:29 PM logoThermo Fisher on an Acquisition Spree, Competition Rife - May 30 at 10:14 AM logoVarian Medical at a 52-Week High: What's Driving the Stock? - May 30 at 10:14 AM logoInogen (INGN) Hits a 52-Week High on Solid Q1, Upbeat View - May 30 at 10:14 AM logoNuVasive Aims for Innovation, Global Growth amid Woes - May 30 at 10:14 AM logoQuintiles IMS Holdings (Q) to Repurchase 10.6M Common Share - May 30 at 10:14 AM logoIDEXX Laboratories Global Growth Solid amid Currency Woes - May 30 at 10:14 AM logoLuminex Co. (LMNX) to Issue $0.06 Quarterly Dividend - May 25 at 6:50 PM logoLuminex Co. (LMNX) Director G Walter Loewenbaum II Sells 25,000 Shares - May 25 at 1:22 PM logoLuminex Corporation Declares Second Quarter Cash Dividend - May 24 at 11:07 AM logoIntegra LifeSciences to Offer aap's LOQTEQ System in the US - May 24 at 11:07 AM logoLabCorp Offers Sera's PreTRM to Assess Preterm Birth Risk - May 24 at 11:07 AM logoLuminex Co. (LMNX) Upgraded by TheStreet to "B-" - May 23 at 5:34 PM logoBruker Corp (BRKR) at 52-Week High: What's Driving the Stock? - May 23 at 10:43 AM logoIDEXX Laboratories (IDXX) Raised to Buy on Solid Prospects - May 23 at 10:43 AM logoHologic (HOLX) Poised on Balanced Growth Amid Currency Woes - May 23 at 10:43 AM logoIntuitive Surgical at 52-Week High: What's Driving the Stock? - May 22 at 10:20 AM logoLuminex Co. (LMNX) Receives Consensus Recommendation of "Hold" from Brokerages - May 19 at 12:52 PM logoHalyard Health Announces New Drainage System, Stock Down - May 18 at 8:54 AM logoGenomic Health's (GHDX) Oncotype DX GPS Test Data Positive - May 16 at 10:43 AM logoCR Bard (BCR) Hits a 52-Week High: What's Driving the Stock? - May 15 at 10:35 AM logoLuminex Co. (LMNX) Expected to Post Quarterly Sales of $75.18 Million - May 14 at 9:24 AM logo$0.08 EPS Expected for Luminex Co. (LMNX) This Quarter - May 12 at 2:16 PM



Luminex Corporation (LMNX) Chart for Monday, July, 24, 2017

This page was last updated on 7/24/2017 by Staff